Skip to content

BioXcel Therapeutics, Inc.

BTAIQ · OTCM

CIK 1720893fmd_1TK0AHR0AHDHEY9EHWRZFZ0R38Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2017 to Jun 30, 2026, 38 periods

Latest annual · FY2025

Millions
Total revenues
1
Gross profit
0
Operating income
(50)
Net income
(70)
Free cash flow
(58)

Latest quarter · Q2 FY2026

Millions
Total revenues
0
Gross profit
0
Operating income
(10)
Net income
(15)
Free cash flow
(6)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+19.6%
Revenue, 5 yearsFY2020 to FY2025
n/m
Net income, 5 yearsFY2020 to FY2025
n/m

BioXcel Therapeutics, Inc. (BTAIQ) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$642,000$2.3 million-71.7%10-K 2026-03-27 · proof
Gross profit$478,000$123,000+288.6%10-K 2026-03-27 · proof
Operating income-$50.5 million-$67.2 million10-K 2026-03-27 · proof
Net income-$69.9 million-$59.6 million10-K 2026-03-27 · proof
Cash from operating activities-$57.6 million-$72 million10-K 2026-03-27 · proof
Free cash flow-$57.6 million-$72 million10-K 2026-03-27 · proof
Total assets$44.9 million$38.3 million+17.2%10-K 2026-03-27 · proof
Total liabilities$140.4 million$131.4 million+6.8%10-K 2026-03-27 · proof
Cash and cash equivalents$28.4 million$29.9 million-4.8%10-K 2026-03-27 · proof
Total debt$109.6 million$102.5 million+6.9%10-K 2026-03-27 · proof
What was BioXcel Therapeutics, Inc. (BTAIQ)'s revenue in fiscal 2025?
BioXcel Therapeutics, Inc. (BTAIQ) reported revenue of $642,000 for fiscal 2025 (the year ended Dec 31, 2025), against $2.3 million the year before (-71.7%). Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What was BioXcel Therapeutics, Inc. (BTAIQ)'s gross profit in fiscal 2025?
BioXcel Therapeutics, Inc. (BTAIQ) reported gross profit of $478,000 for fiscal 2025 (the year ended Dec 31, 2025), against $123,000 the year before (+288.6%). Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What was BioXcel Therapeutics, Inc. (BTAIQ)'s operating income in fiscal 2025?
BioXcel Therapeutics, Inc. (BTAIQ) reported operating income of -$50.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$67.2 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What was BioXcel Therapeutics, Inc. (BTAIQ)'s net income in fiscal 2025?
BioXcel Therapeutics, Inc. (BTAIQ) reported net income of -$69.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$59.6 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What was BioXcel Therapeutics, Inc. (BTAIQ)'s cash from operating activities in fiscal 2025?
BioXcel Therapeutics, Inc. (BTAIQ) reported cash from operating activities of -$57.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$72 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What was BioXcel Therapeutics, Inc. (BTAIQ)'s free cash flow in fiscal 2025?
BioXcel Therapeutics, Inc. (BTAIQ) reported free cash flow of -$57.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$72 million the year before. Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What are BioXcel Therapeutics, Inc. (BTAIQ)'s total assets?
As of Dec 31, 2025, BioXcel Therapeutics, Inc. (BTAIQ) reported total assets of $44.9 million, against $38.3 million a year earlier (+17.2%). Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What are BioXcel Therapeutics, Inc. (BTAIQ)'s total liabilities?
As of Dec 31, 2025, BioXcel Therapeutics, Inc. (BTAIQ) reported total liabilities of $140.4 million, against $131.4 million a year earlier (+6.8%). Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What are BioXcel Therapeutics, Inc. (BTAIQ)'s cash and cash equivalents?
As of Dec 31, 2025, BioXcel Therapeutics, Inc. (BTAIQ) reported cash and cash equivalents of $28.4 million, against $29.9 million a year earlier (-4.8%). Source: the 10-K filed with the SEC on Mar 27, 2026. SEC
What is BioXcel Therapeutics, Inc. (BTAIQ)'s total debt?
As of Dec 31, 2025, BioXcel Therapeutics, Inc. (BTAIQ) reported total debt of $109.6 million, against $102.5 million a year earlier (+6.9%). Source: the 10-K filed with the SEC on Mar 27, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BTAIQ&period_type=annual&limit=5"

Information only, not investment advice.